Last reviewed 2026-04-20 · How we verify

METHIXENE HYDROCHLORIDE

FDA-approved approved Small molecule Quality 0/100

METHIXENE HYDROCHLORIDE is a drug. It is currently FDA-approved (first approved 1982).

Methixene Hydrochloride is a marketed drug with a key composition patent expiring in 2028. The drug's market position and primary indication are not specified, but it holds a significant competitive advantage due to its patent protection until 2028. The primary risk is the potential increase in competition post-patent expiry in 2028.

At a glance

Generic name	METHIXENE HYDROCHLORIDE
Modality	Small molecule
Phase	FDA-approved
First approval	1982

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
FDA label	Mechanism, indications, dosing, boxed warnings, drug interactions

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

METHIXENE HYDROCHLORIDE CI brief — competitive landscape report
METHIXENE HYDROCHLORIDE updates RSS · CI watch RSS

Frequently asked questions about METHIXENE HYDROCHLORIDE

What is METHIXENE HYDROCHLORIDE?

METHIXENE HYDROCHLORIDE is a Small molecule drug.

When was METHIXENE HYDROCHLORIDE approved?

METHIXENE HYDROCHLORIDE was first approved on 1982.

What development phase is METHIXENE HYDROCHLORIDE in?

METHIXENE HYDROCHLORIDE is FDA-approved (marketed).

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing